{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T20:40:01Z","timestamp":1748551201727,"version":"3.41.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T00:00:00Z","timestamp":1438300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Bunderministerium fuer Bildung und Forschung","award":["01KG0910"],"award-info":[{"award-number":["01KG0910"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00406-015-0624-y","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T09:28:59Z","timestamp":1438248539000},"page":"513-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The SWITCH study: rationale and design of the trial"],"prefix":"10.1007","volume":"266","author":[{"given":"Stephan","family":"Heres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana Meliu","family":"Cirjaliu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Dehelean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin Petre","family":"Matei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia Marina","family":"Podea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorina","family":"Sima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Stecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,31]]},"reference":[{"key":"624_CR1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","volume":"60","author":"O Agid","year":"2003","unstructured":"Agid O, Kapur S, Arenovich T, Zipursky RB (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60:1228\u20131235","journal-title":"Arch Gen Psychiatry"},{"key":"624_CR2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2008.03.016","volume":"102","author":"O Agid","year":"2008","unstructured":"Agid O, Kapur S, Warrington L, Loebel A, Siu C (2008) Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res 102:241\u2013248","journal-title":"Schizophr Res"},{"key":"624_CR3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441\u2013449","journal-title":"Am J Psychiatry"},{"key":"624_CR4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/schbul\/sbm134","volume":"34","author":"H Ascher-Svanum","year":"2008","unstructured":"Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A (2008) Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 34:1163\u20131171","journal-title":"Schizophr Bull"},{"key":"624_CR5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TRE Barnes","year":"1989","unstructured":"Barnes TRE (1989) A rating scale for drug induced akathisia. Br J Psychiatry 154:672\u2013676","journal-title":"Br J Psychiatry"},{"key":"624_CR6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0924-977X(96)00392-6","volume":"7","author":"CM Beasley","year":"1997","unstructured":"Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen J-N (1997) Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7:125\u2013137","journal-title":"Eur Neuropsychopharmacol"},{"key":"624_CR7","doi-asserted-by":"crossref","first-page":"e8668","DOI":"10.1136\/bmj.e8668","volume":"346","author":"ML Bell","year":"2013","unstructured":"Bell ML, Kenward MG, Fairclough DL, Horton NJ (2013) Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ 346:e8668","journal-title":"BMJ"},{"issue":"Suppl. 37","key":"624_CR8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1192\/S0007125000293653","volume":"174","author":"F Bymaster","year":"1999","unstructured":"Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO (1999) Olanzapine: a basic science update. Br J Psychiatry 174(Suppl. 37):36\u201340","journal-title":"Br J Psychiatry"},{"key":"624_CR9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","volume":"37","author":"FP Bymaster","year":"1999","unstructured":"Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO (1999) Antagonism by olanzapine of dopamine d1, serotonin(2), muscarinic, histamine h-1 and alpha(1),-adrenergic receptors in vitro. Schizophr Res 37:107\u2013122","journal-title":"Schizophr Res"},{"key":"624_CR10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.schres.2008.12.004","volume":"108","author":"A Ciudad","year":"2009","unstructured":"Ciudad A, Alvarez E, Bobes J, San L, Polavieja P, Gilaberte I (2009) Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophr Res 108:214\u2013222","journal-title":"Schizophr Res"},{"key":"624_CR11","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1176\/appi.ajp.160.11.2063","volume":"160","author":"CU Correll","year":"2003","unstructured":"Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM (2003) Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 160:2063\u20132065","journal-title":"Am J Psychiatry"},{"key":"624_CR12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","volume":"60","author":"JM Davis","year":"2003","unstructured":"Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553\u2013564","journal-title":"Arch Gen Psychiatry"},{"key":"624_CR13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.schres.2007.01.010","volume":"92","author":"M Hert de","year":"2007","unstructured":"de Hert M, van Winkel R, Wampers M, Kane J, van Os J, Peuskens J (2007) Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 92:68\u201373","journal-title":"Schizophr Res"},{"key":"624_CR14","doi-asserted-by":"crossref","unstructured":"Duggan L, Fenton M, Dardennes RM, El-Dosoky A (2004) Olanzapine for schizophrenia (cochrane review). In: The cochrane library. John Wiley & Sons Ltd, Chichester","DOI":"10.1002\/14651858.CD001359.pub2"},{"key":"624_CR15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.schres.2006.06.002","volume":"86","author":"E Dunayevich","year":"2006","unstructured":"Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D (2006) Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res 86:300\u2013308","journal-title":"Schizophr Res"},{"key":"624_CR16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/JCP.0b013e318167269d","volume":"28","author":"R Emsley","year":"2008","unstructured":"Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J (2008) Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 28:210\u2013213","journal-title":"J Clin Psychopharmacol"},{"key":"624_CR17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15622970500483177","volume":"7","author":"P Falkai","year":"2006","unstructured":"Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ (2006) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 7:5\u201340","journal-title":"World J Biol Psychiatry"},{"key":"624_CR18","volume-title":"Behandlungsleitlinie schizophrenie","author":"W Gaebel","year":"2006","unstructured":"Gaebel W, Falkai P, Weinmann S, Wobrock T (2006) Behandlungsleitlinie schizophrenie. Steinkopff, Darmstadt"},{"key":"624_CR19","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4088\/JCP.v68n1116","volume":"68","author":"W Gaebel","year":"2007","unstructured":"Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherubl MC, Kuhn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlosser R, Schmidt LG, Schmitt A, Jager M, Buchkremer G, Falkai P, Klingberg S, Kopcke W, Maier W, Hafner H, Ohmann C, Salize HJ, Schneider F, Moller HJ (2007) Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the german research network on schizophrenia. J Clin Psychiatry 68:1763\u20131774","journal-title":"J Clin Psychiatry"},{"key":"624_CR20","volume-title":"Ecdeu assessment manual for psychopharmacology","author":"U Guy","year":"1976","unstructured":"Guy U (1976) Ecdeu assessment manual for psychopharmacology. National Institute of Mental Health, Rockville, MD"},{"key":"624_CR21","first-page":"218","volume-title":"Ecdeu assessment manual for psychopharmacology, revised (dhew publ no adm 76-338)","author":"W Guy","year":"1976","unstructured":"Guy W (1976) Clinical global impression. Ecdeu assessment manual for psychopharmacology, revised (dhew publ no adm 76-338). National Institute of Mental Health, Rockville, MD, pp 218\u2013222"},{"key":"624_CR22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2011.02.011","volume":"128","author":"K Hatta","year":"2011","unstructured":"Hatta K, Otachi T, Sudo Y, Hayakawa T, Ashizawa Y, Takebayashi H, Hayashi N, Hamakawa H, Ito S, Nakase R, Usui C, Nakamura H, Hirata T, Sawa Y, JAST Study Group (2011) Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophr Res 128:127\u2013135","journal-title":"Schizophr Res"},{"key":"624_CR23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.schres.2007.01.014","volume":"93","author":"L Helldin","year":"2007","unstructured":"Helldin L, Kane JM, Karilampi U, Norlander T, Archer T (2007) Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res 93:160\u2013168","journal-title":"Schizophr Res"},{"key":"624_CR24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","volume":"13","author":"TP Hogan","year":"1983","unstructured":"Hogan TP, Awad AG, Eastwood R (1983) A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13:177\u2013183","journal-title":"Psychol Med"},{"key":"624_CR25","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE, EUFEST Study Group (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085\u20131097","journal-title":"Lancet"},{"key":"624_CR26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A (1987) The positive and negative symptome scale (PANSS) for schizophrenia. Schizophr Bull 13:261\u2013275","journal-title":"Schizophr Bull"},{"key":"624_CR27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2008.02.021","volume":"102","author":"BJ Kinon","year":"2008","unstructured":"Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM (2008) Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 102:230\u2013240","journal-title":"Schizophr Res"},{"key":"624_CR28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","volume":"35","author":"BJ Kinon","year":"2010","unstructured":"Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM (2010) Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35:581\u2013590","journal-title":"Neuropsychopharmacology"},{"key":"624_CR29","first-page":"309","volume":"29","author":"BJ Kinon","year":"1993","unstructured":"Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, Weiden P (1993) Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 29:309\u2013314","journal-title":"Psychopharmacol Bull"},{"key":"624_CR30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.31887\/DCNS.2010.12.3\/mlambert","volume":"12","author":"M Lambert","year":"2010","unstructured":"Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D (2010) Remission in schizophrenia: validity, frequency, predictors, and patients\u2019 perspective 5\u00a0years later. Dialogues Clin Neurosci 12:393\u2013407","journal-title":"Dialogues Clin Neurosci"},{"key":"624_CR31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","volume":"114","author":"Y Lecrubier","year":"2006","unstructured":"Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S (2006) The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand 114:319\u2013327","journal-title":"Acta Psychiatr Scand"},{"key":"624_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/appi.ajp.161.1.1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161:1\u201356","journal-title":"Am J Psychiatry"},{"key":"624_CR33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-007-0857-1","volume":"194","author":"S Leucht","year":"2007","unstructured":"Leucht S, Beitinger R, Kissling W (2007) On the concept of remission in schizophrenia. Psychopharmacology 194:453\u2013461","journal-title":"Psychopharmacology"},{"key":"624_CR34","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","volume":"57","author":"S Leucht","year":"2005","unstructured":"Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005) Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57:1543\u20131549","journal-title":"Biol Psychiatry"},{"key":"624_CR35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4088\/JCP.v68n0301","volume":"68","author":"S Leucht","year":"2007","unstructured":"Leucht S, Busch R, Kissling W, Kane JM (2007) Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 68:352\u2013360","journal-title":"J Clin Psychiatry"},{"key":"624_CR36","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962","journal-title":"Lancet"},{"key":"624_CR37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","volume":"166","author":"S Leucht","year":"2009","unstructured":"Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152\u2013163","journal-title":"Am J Psychiatry"},{"key":"624_CR38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1176\/appi.ajp.159.2.180","volume":"159","author":"S Leucht","year":"2002","unstructured":"Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002) Amisulpride, an unusual \u201catypical\u201d antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159:180\u2013190","journal-title":"Am J Psychiatry"},{"key":"624_CR39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.schres.2008.01.018","volume":"101","author":"S Leucht","year":"2008","unstructured":"Leucht S, Shamsi SA, Busch R, Kissling W, Kane JM (2008) Predicting antipsychotic drug response\u2014replication and extension to six weeks in an international olanzapine study. Schizophr Res 101:312\u2013319","journal-title":"Schizophr Res"},{"key":"624_CR40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","volume":"101","author":"PL Morosini","year":"2000","unstructured":"Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R (2000) Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101:323\u2013329","journal-title":"Acta Psychiatr Scand"},{"key":"624_CR41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00004850-200403000-00002","volume":"19","author":"A Mortimer","year":"2004","unstructured":"Mortimer A, Martin S, Loo H, Peuskens J (2004) A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6\u00a0months in the treatment of schizophrenia. Int Clin Psychopharmacol 19:63\u201369","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl 4","key":"624_CR42","doi-asserted-by":"crossref","first-page":"S391","DOI":"10.1016\/S0924-977X(01)00110-9","volume":"11","author":"D Naber","year":"2001","unstructured":"Naber D, Karow A (2001) Good tolerability equals good results: the patient\u2019s perspective. Eur Neuropsychopharmacol 11(Suppl 4):S391\u2013S396","journal-title":"Eur Neuropsychopharmacol"},{"key":"624_CR43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-9964(00)00166-3","volume":"50","author":"D Naber","year":"2001","unstructured":"Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B, Rajonk F (2001) Improvement of schizophrenic patients\u2019 subjective well-being under atypical antipsychotic drugs. Schizophr Res 50:79\u201388","journal-title":"Schizophr Res"},{"key":"624_CR44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)36394-3","volume":"280","author":"G Perrault","year":"1997","unstructured":"Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B (1997) Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic d2\/d3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73\u201382","journal-title":"J Pharmacol Exp Ther"},{"key":"624_CR45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1998.tb10044.x","volume":"98","author":"A Puech","year":"1998","unstructured":"Puech A, Fleurot O, Rein W (1998) Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. Haloperidol. Acta Psychiatr Scand 98:65\u201372","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"624_CR46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","volume":"172","author":"MT Samara","year":"2015","unstructured":"Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, M\u00f6ller HJ, Pelayo-Ter\u00e1n JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S (2015) Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172:617\u2013629","journal-title":"Am J Psychiatry"},{"key":"624_CR47","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.eurpsy.2007.06.005","volume":"22","author":"L San","year":"2007","unstructured":"San L, Ciudad A, Alvarez E, Bobes J, Gilaberte I (2007) Symptomatic remission and social\/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiatry 22:490\u2013498","journal-title":"Eur Psychiatry"},{"key":"624_CR48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-0447.1993.tb03335.x","volume":"87","author":"A Shalev","year":"1993","unstructured":"Shalev A, Hermesh H, Rothberg J, Munitz H (1993) Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr Scand 87:86\u201391","journal-title":"Acta Psychiatr Scand"},{"key":"624_CR49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"M Simpson","year":"1970","unstructured":"Simpson M, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11\u201319","journal-title":"Acta Psychiatr Scand"},{"key":"624_CR50","first-page":"1","volume":"45","author":"S Buuren van","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K (2011) Mice: multivariate imputation by chained equations in R. J Stat Softw 45:1\u201367","journal-title":"J Stat Softw"},{"key":"624_CR51","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","volume":"164","author":"TS Stroup","year":"2007","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK, Investigators C (2007) Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 164:415\u2013427","journal-title":"Am J Psychiatry"},{"key":"624_CR52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-007-0872-2","volume":"195","author":"T Suzuki","year":"2007","unstructured":"Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H (2007) How effective is it to sequentially switch among olanzapine, quetiapine and risperidone?\u2014a randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology 195:285\u2013295","journal-title":"Psychopharmacology"},{"key":"624_CR53","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1176\/ajp.2006.163.11.2000","volume":"163","author":"J Os van","year":"2006","unstructured":"van Os J, Drukker M, a Campo J, Meijer J, Bak M, Delespaul P (2006) Validation of remission criteria for schizophrenia. Am J Psychiatry 163:2000\u20132002","journal-title":"Am J Psychiatry"},{"key":"624_CR54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eurpsy.2006.09.003","volume":"21","author":"JM Vanelle","year":"2006","unstructured":"Vanelle JM, Douki S (2006) A double-blind randomised comparative trial of amisulpride versus olanzapine for 2\u00a0months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry 21:523\u2013530","journal-title":"Eur Psychiatry"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-015-0624-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-015-0624-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-015-0624-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T20:25:08Z","timestamp":1748550308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-015-0624-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,31]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1007\/s00406-015-0624-y","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"type":"print","value":"0940-1334"},{"type":"electronic","value":"1433-8491"}],"subject":[],"published":{"date-parts":[[2015,7,31]]}}}